Treatment Use Study for Advanced Melanoma.

Treatment Use Study of CP-675,206 for Advanced Melanoma

NCT00584493CI-TRIAL-00002885no longer availableClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Advanced Unresectable Melanoma	Melanoma	CURATED_BROADER	0.78

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
CP-675,206	Drug	Tremelimumab	ALIAS

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Advanced melanoma with life expectancy of at least 6 months.
* Melanoma must be considered unresectable.
* Patients with stable, treated brain mets must be stable clinically and radiographically and off steroids for at least one month.

Exclusion Criteria:

* Patients must not be eligible for participation in any ongoing CP-675,206 clinical studies currently open for enrollment.
* History of chronic inflammatory or autoimmune disease.
* History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, active colitis, history of diverticulitis.

References

Publications (0)

Data not yet available

No reference posted for this study.